FINCH filgotinib Phase 3 program initiated in rheumatoid

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
FINCH filgotinib Phase 3 program initiated in rheumatoid arthritis
  • Three studies addressing a broad population of patients with active rheumatoid arthritis
  • Filgotinib 100 mg and 200 mg, once daily dosing in males and females worldwide in combination- and as monotherapy

MECHELEN, Belgium, Aug. 22, 2016 (GLOBE NEWSWIRE) --     Galapagos NV (Euronext & NASDAQ: GLPG) reports the initiation of the FINCH global Phase 3 program investigating the efficacy and safety of 100 mg and 200 mg filgotinib once daily, in rheumatoid arthritis (RA) patient populations, ranging from early stage to biologic-experienced patients. 

The FINCH program includes three studies with filgotinib. FINCH 1 is a 52-week, randomized, placebo- and adalimumab-controlled study in combination with methotrexate (MTX) in an expected 1,650 patients who have had inadequate response to MTX. The primary endpoint is ACR20 [1] at week 12. The study will also include radiographic assessment at weeks 24 and 52.

FINCH 2 is a 24-week, randomized, placebo-controlled study in an expected 423 patients who are on conventional disease-modifying anti-rheumatic drugs (cDMARD), and have had an inadequate response to biological treatment. The primary endpoint is ACR20 at week 12.

FINCH 3 is a 52-week, randomized study in an expected 1,200 MTX-naïve patients to study filgotinib in combination with MTX, as well as monotherapy. The primary endpoint is ACR20 at week 24. Radiographic progression will also be assessed.

"The FINCH program, led by our collaboration partner Gilead Sciences, Inc., is designed to enable a comprehensive evaluation of 100 mg and 200 mg filgotinib once daily in early stage to biologic-resistant RA patient populations," said Piet Wigerinck, Chief Scientific Officer at Galapagos. "Preparations are well underway to also initiate studies with filgotinib in Crohn's disease and ulcerative colitis in Q4 of this year."

The FINCH program in RA will be conducted in the United States and Europe to start, with other regions to follow. For more information, visit www.clinicaltrials.gov .

Galapagos and Gilead have entered into a global collaboration for the development and commercialization of filgotinib for inflammatory indications. Filgotinib is an investigational agent and its safety and efficacy have not been established. For more information, check www.glpg.com/filgotinib .

About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises a pipeline of Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib; in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta , has approximately 460 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com .

Contacts

Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate Communications Director Communications
+1 781 460 1784 Paul van der Horst Director IR & Business Development +31 6 53 725 199 +31 6 53 591 999 communications@glpg.com  
ir@glpg.com  

Forward-Looking Statements This release may contain forward-looking statements, including statements regarding the anticipated timing of clinical studies with filgotinib. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs in rheumatoid arthritis, Crohn's disease and/or ulcerative colitis may not support registration or further development of filgotinib due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties (including its collaboration partner for filgotinib, Gilead), and estimating the commercial potential of Galapagos' product candidates. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on form 20-F filed with the SEC and subsequent filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

[1] American College of Rheumatology 20% (ACR20) response rate signifies a 20% or greater improvement in the number of swollen and tender joints as well as a 20% or greater improvement in three out of five other disease-activity measures. ACR 50 and ACR70 reflect the same, respectively for 50% and 70% response rates.

FINCH filgotinib Phase 3 program initiated in RA http://hugin.info/133350/R/2036608/758706.pdf

HUG#2036608

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 114

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
OFRM Recall Leaves Investors Facing Hard Questions

Updated Category News Views 96

Nothing wrecks a young consumer brand’s glow faster than a recall involving toddlers, and Once Upon A Farm has just learned that lesson in the ugliest possible way. On November 2, 2026, shares of NYSE:OFRM fell 37% to close at $9.44. That left the stock roughly 47% below its $18 IPO price. Those are not the garden-variety bruises of a weak quarter. That is the market...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 165

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
J. Harmon Tests a Smarter Cannabis Accessory Niche

Updated Category News Views 138

Aisle Space Is the Real Prize Most cannabis accessory launches arrive dressed up like a gimmick and disappear before anyone has reordered them. J. Harmon has a more sensible target: give women products that look deliberate, work in everyday routines and do not demand designer-level money. The brand is set to debut at MJBizCon 2026 in Las Vegas, with LUVBUDS handling...

Continue Reading
L’Oréal’s Women of Worth Shows Why Brand Patience Matters

Updated Category News Views 120

Twenty-one years is a long time to keep a corporate promise from turning into wallpaper. L’Oréal Paris gathered its 2026 Women of Worth class at the Ebell in Los Angeles on November 18, recognizing 10 nonprofit leaders working on problems that do not yield to a glitzy evening or a tidy slogan. That distinction matters. Cancer survivorship, trafficking prevention,...

Continue Reading
DJI Puts 3D Conservation Tools to Work Across Segovia

Updated Category News Views 163

Stone monuments do not care about marketing slogans; they care whether somebody notices the crack before winter gets hold of it. That is why DJI’s World Heritage 3D Conservation Initiative in Segovia lands as more than a shiny drone-company ceremony. The company gathered winning 3D fly-through work from its first initiative, but the useful bit was the case for turning...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 35

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Nike Locks In Chicago Marathon Partnership Through 2036 Deal

Updated Category News Views 104

Twenty-eight miles of pavement, training plans, and branded shoes are not a quarterly earnings release, but Nike just made a very long-term statement in Chicago. The company and the Bank of America Chicago Marathon have extended their partnership through 2036, preserving a relationship that began in 2008. For a brand rebuilding credibility with runners, that kind of...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 141

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Rox Taps Dynamics 365 Without Forcing a CRM Reset Yet

Updated Category News Views 237

Enterprise software buyers hate renovations when a useful extension will do. Rox’s new integration with Microsoft Dynamics 365 Sales, announced November 19, 2026, is built around that unglamorous but very real fact. The company is not asking a Global 2000 sales organization to rip out its customer system, retrain everybody, and pray an AI layer somehow pays for the...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Update for Centene Investors on Class Action Case

Updated Category News Views 125

Overview of the Class Action Lawsuit Against Centene A critical reminder has emerged for investors of Centene Corporation regarding the ongoing class action lawsuit. The litigation is focused on allegations that may involve significant losses for shareholders, particularly those whose financial stakes in the company have been adversely affected. Lead Plaintiff Deadline...

Continue Reading
Keith Gabel and Sercomm to Unveil Innovations at SCTE TechExpo

Updated Category News Views 299

Keith Gabel to Join Sercomm at SCTE TechExpo for Product Launch Sercomm, a renowned provider in the telecom and broadband sector, is set to make waves at the upcoming SCTE TechExpo. The company is excited to announce that U.S. Paralympic and World Champion snowboarder, Keith Gabel, will be a special guest during this significant event. This collaboration spotlights not...

Continue Reading
Crafting a Small Biz Site That Converts Consistently

Updated Category News Views 28

Making an Impression: Small Biz Website Must-Haves First impressions aren't just for dinner parties or nervous job interviews. They're the bread and butter of small business websites, and if you flub it, your visitors are gone before you can blink. Sean O'Kelly, a digital marketing whiz, throws down some knowledge in HelloNation, drilling into what makes a small business...

Continue Reading
Cooper Standard Launches Innovative FlexiCore Thermoplastic Seal

Updated Category News Views 88

Revolutionizing Automotive Sealing Solutions Cooper Standard, a premier global supplier in sealing and fluid handling, is once again leading the industry with the introduction of the FlexiCore™ Thermoplastic Body Seal. This innovative product represents a significant leap in automotive sealing technology, aiming to provide a more sustainable, lightweight, and efficient...

Continue Reading
Coupang Securities Class Action: Investors' Rights Explained

Updated Category News Views 166

Coupang Securities Class Action Overview In the world of investments, staying informed is crucial, especially when facing legal challenges. The case involving Coupang, Inc. has drawn significant attention recently, primarily due to allegations of securities fraud linked to a data breach and subsequent stock decline. This case emphasizes the importance of understanding how...

Continue Reading